Although I am happy to some degree that Vyrologix will be “trialed up” for Alzheimer’s and stroke”, it does muddy the water a bit when we are declaring Cytodyn’s future to be Oncology..so I would want Dr Kelly to clarify his position on his vision for the company and how divergent trials align with the Oncology pursuit.